NASDAQ:APVO
Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc. reported net income of −$26.0M in fiscal 2025. The diluted share count rose 41038.9%.Summary generated from Aptevo Therapeutics Inc.'s SEC filings. Latest annual report filed Mar 26, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−234.6%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+41038.9%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 12 | 3 | n/a | n/a | n/a |
| Operating income | −21 | −29 | −29 | −25 | −26 |
| Net income | −28 | 8 | −17 | −24 | −26 |
| Free cash flow | −22 | −21 | n/a | n/a | n/a |
Recent filings
- 8-KOther events
Sep 24, 2026 - 8-KResults of a shareholder vote
Sep 23, 2026 - 8-KOther events
Sep 3, 2026 - DEF 14AProxy statement
Aug 31, 2026 - S-1Registration statement
Aug 21, 2026 - 8-KResults of a shareholder vote
Aug 21, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 14, 2026 - 8-KResults of operations and financial condition
Aug 14, 2026